FURIN and neoplasm: For example, the introduction of a tumor protease binding site in the A-subunit in place of the furin cleavage site would biologically “switch-off” Stx toxicity without affecting B-subunit binding and retrograde transport, delivering the engineered molecule to its intracellular target.